With your support, The MPN Research Foundation has aided in research that has resulted in a better understanding of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis. A recent article titled “JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML” was published in the Journal of Experimental Medicine and is partially funded by MPNRF and our supporters through the Interferon Initiative. An accompanying article also published in the Journal of Experiemental Medicine called “A knockout combination for MPN stem cells” provides helpful commentary about the study from researchers Dr. Megan Bywater and Dr. Steven W. Lane. Click HERE to learn more. The MPNRF Interferon (IFN) Initiative is a multi-center project that has brought together internationally recognized experts in both blood and solid tumors to determine how cytokine-driven pathways affect the trajectory of the MPNs, a closely-related group of progressive blood cancers. The collaboration among this group of scientists speaks to their drive to answer these questions: >
  • How and why does targeting the IFN pathway reduce the burden of mutated stem cells in MPN patients?
  • Why is targeting this pathway effective for some MPN patients but not others?
  • Why are the positive effects of targeting this pathway not permanent?
  • Receive updates on the latest MPN news & events.